Division of Thoracic Surgery, Department of Surgery, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Department of General Surgery, Kumihama Hospital, Kyotango City, Kyoto, Japan.
Ann Surg Oncol. 2022 Sep;29(9):5699-5707. doi: 10.1245/s10434-022-11835-3. Epub 2022 Jun 2.
Both plasma fibrinogen level and neutrophil-to-lymphocyte ratio (NLR) are associated with malignant potential in different cancer types. The current study evaluated the use of combined plasma fibrinogen level and NLR (F-NLR) as a prognostic predictor in patients with non-small cell lung cancer (NSCLC).
Data collected from 279 patients with resectable NSCLC were retrospectively reviewed. Patients were divided into three groups based on the F-NLR score: score 2, high fibrinogen level (≥350 mg/dL) and high NLR (≥2.5); score 1, either high fibrinogen level or high NLR; and score 0, neither abnormal. Overall survival (OS) and relapse-free survival (RFS) were evaluated using the Kaplan-Meier method and log-rank test. Cox proportional hazard model was used to assess prognostic factors.
Numbers of patients with F-NLR score of 0, 1, and 2 were 122 (43.7%), 105 (37.6%), and 52 (18.6%), respectively. The F-NLR was found to be significantly associated with age, male sex, heavy smoking history, high pT status and pathological stage, and nonadenocarcinoma. Moreover, the OS and RFS significantly differed according to the F-NLR score (P < 0.001, P = 0.003). A multivariate analysis revealed that a high F-NLR score (≥1) was an independent poor prognostic factor for OS (P = 0.027). In subgroup analyses, an adverse prognostic impact of the F-NLR score on OS was identified regardless of nodal involvement or pathological stage.
The F-NLR score, which is based on histological inflammation and coagulability, could be a potential prognostic indicator in patients with resectable NSCLC.
血浆纤维蛋白原水平和中性粒细胞与淋巴细胞比值(NLR)均与不同癌症类型的恶性潜能相关。本研究评估了联合应用血浆纤维蛋白原水平和 NLR(F-NLR)作为可切除性非小细胞肺癌(NSCLC)患者的预后预测指标的作用。
回顾性分析了 279 例可切除性 NSCLC 患者的数据。根据 F-NLR 评分将患者分为三组:评分 2,高纤维蛋白原水平(≥350mg/dL)和高 NLR(≥2.5);评分 1,纤维蛋白原水平高或 NLR 高;评分 0,两者均正常。采用 Kaplan-Meier 法和对数秩检验评估总生存期(OS)和无复发生存期(RFS)。采用 Cox 比例风险模型评估预后因素。
F-NLR 评分为 0、1 和 2 的患者分别为 122 例(43.7%)、105 例(37.6%)和 52 例(18.6%)。F-NLR 与年龄、男性、大量吸烟史、高 pT 状态和病理分期以及非腺癌显著相关。此外,F-NLR 评分与 OS 和 RFS 显著相关(P<0.001,P=0.003)。多因素分析显示,高 F-NLR 评分(≥1)是 OS 的独立不良预后因素(P=0.027)。亚组分析显示,无论淋巴结受累情况或病理分期如何,F-NLR 评分对 OS 的预后影响均为不利。
基于组织学炎症和凝血性的 F-NLR 评分可能是可切除性 NSCLC 患者的一个潜在预后指标。